open access

Vol 1, No 3 (2005)
Review paper
Published online: 2005-09-17
Get Citation

Chronic lymphocytic leukemia treatment based on the results of recent clinical trials

Anna Szmigielska-Kapłon, Tadeusz Robak
Onkol. Prak. Klin 2005;1(3):141-150.

open access

Vol 1, No 3 (2005)
REVIEW ARTICLES
Published online: 2005-09-17

Abstract

Chronic lymphocytic leukemia is characterized by accumulation of mature, resting lymphocytes with low mitotic index. Therapeutic strategies employed in chronic lymphocytic leukemia depend on stage of the disease and its tendency to progression. Patients with stable disease are often observed only for many years without treatment.
Chemotherapeutic armamentarium consists of alkylating agents, purine nucleoside analogs and monoclonal antibodies against CD20 antigen (rituximab) and against CD52 (alemtuzumab). Randomized trials have shown higher response rates including complete response rates and prolongation of disease free survival in case of purine nucleoside analogs as compared with alkylating agents. Monoclonal antibodies especially alemtuzumab are highly active in relapsed or refractory to standard treatment cases. Combination of rituximab with PNA enhances its efficacy.

Abstract

Chronic lymphocytic leukemia is characterized by accumulation of mature, resting lymphocytes with low mitotic index. Therapeutic strategies employed in chronic lymphocytic leukemia depend on stage of the disease and its tendency to progression. Patients with stable disease are often observed only for many years without treatment.
Chemotherapeutic armamentarium consists of alkylating agents, purine nucleoside analogs and monoclonal antibodies against CD20 antigen (rituximab) and against CD52 (alemtuzumab). Randomized trials have shown higher response rates including complete response rates and prolongation of disease free survival in case of purine nucleoside analogs as compared with alkylating agents. Monoclonal antibodies especially alemtuzumab are highly active in relapsed or refractory to standard treatment cases. Combination of rituximab with PNA enhances its efficacy.
Get Citation

Keywords

chronic lymphocytic leukemia; alkylating agents; purine nucleoside analogs; monoclonal antibodies

About this article
Title

Chronic lymphocytic leukemia treatment based on the results of recent clinical trials

Journal

Oncology in Clinical Practice

Issue

Vol 1, No 3 (2005)

Article type

Review paper

Pages

141-150

Published online

2005-09-17

Bibliographic record

Onkol. Prak. Klin 2005;1(3):141-150.

Keywords

chronic lymphocytic leukemia
alkylating agents
purine nucleoside analogs
monoclonal antibodies

Authors

Anna Szmigielska-Kapłon
Tadeusz Robak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl